Intensive insulin therapy for acute hyperglycemia

AACN Advanced Critical Care

Volumn 18, Issue 2, 2007, Pages 200-212

  Read, Julia Lindeman ^a   Cheng, Eugene Y ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Diabetes; Glycemic control; Hyperglycemia; Intensive insulin therapy

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ACUTE DISEASE; CLINICAL PROTOCOL; COST OF ILLNESS; CRITICAL ILLNESS; DRUG MONITORING; EDUCATION; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HOSPITAL PERSONNEL; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE; MEDICAL RECORD; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PROGRAM DEVELOPMENT; QUALITY CONTROL; REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; BENCHMARKING; CAUSALITY; CLINICAL PROTOCOLS; COST OF ILLNESS; CRITICAL ILLNESS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTENSIVE CARE; MEDICAL RECORDS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PERSONNEL, HOSPITAL; PROGRAM DEVELOPMENT; PROGRAM EVALUATION;

EID: 34250630101     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: 10.1097/01.AACN.0000269264.22041.1c     Document Type: Review

References (51)

1. Turina M. Impact of diabetes mellitus and metabolic disorders. Surg Clin North Am. 2005;85:1153-1161.
2. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787-835.
3. Haller MJ. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am. 2005;52:1553-1578.
4. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
5. Bochicchio GV, Sung J, Joshi M, et al. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma. 2005;58:921-924.
6. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically Ill patients. Mayo Clinic Proc. 2003;78:1471-1478.
7. US Dept of Health and Human Services. U.S. Center for Health Statistics: 1997 National Discharge Survey. Washington, DC: US Dept of Health and Human Services; 1999.
8. Levetan CS, Passar M, Jablonski K, et al. Unrecognized diabetes among hospitalized patients. Diabetes Care. 1998;21:246-249.
9. Frankenfield DC, Omert LA, Bandellino MM, et al. Correlation between measured energy expenditure and clinically obtained variables in trauma and sepsis patients. J Parenter Enteral Nutr. 1994;18:398-403.
10. Centers for Disease Control and Prevention. National diabetes fact sheet (2005). Available at http://www.cdc.gov/diabetes/pubs/estimates05.htm. Accessed December 2006.
11. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917-932.
12. Office of the Assistant Secretary for Planning and Evaluation. ASPE Issue Brief. Washington, DC: Policy Information Center, US Dept of Health and Human Services; May 2005.
13. Van den Berghe et al. Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med. 2006;34:612-616.
14. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
15. Krinsley JS, Jones RL. Cost analysis of intensive glycemic control in critically ill adult patients. Chest. 2006;129:644-650.
16. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34:146-154.
17. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553-591.
18. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-2072.
19. Alexiewicz J, Kumar D, Smogorzewski M, et al. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med. 1995;123:919-924.
20. Brodsky SV, Morrishow AM, Dharia N, et al. Glucose scavenging of nitric oxide. Am J Renal Phys. 2001;280:F480-F486.
21. Sheetz M, King G. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288:2579-2588.
22. Sato N, Kashima K, Ohtani K, et al. Elpalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients. Diabetes Care. 1997;20:995-998.
23. Von Kanel R, Mills P, Dimsdale J. Short-term hyperglycemia induces lymphopenia and lymphocyte subset redistribution. Life Sci. 2001;69:255-256.
24. Black CT, Hennessey PJ, Andrassy RJ. Short-term hyperglycemia depresses immunity through nonenzymatic glycosylation of circulating immunoglobulin. J Trauma. 1990;30:830-832.
25. Raghavan M, Marik PE. Stress hyperglycemia and adrenal insufficiency in the critically ill. Semin Respir Crit Care Med. 2006;27:274-285.
26. Bagdade J, Root R, Bulger R. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes. 1974;23:9-15.
27. Bouter KP, Meyling FH, Hoekstra JB, Masurel N, Erkelens DW, Diepersloot RJ. Influence of blood glucose levels on peripheral lymphocytes in patients with diabetes mellitus. Diabetes Res. 1992;19:77-80.
28. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461.
29. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: longterm results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626-2632.
30. Furnary AP, Gao G, Grunkemeire GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003;125:1007.
31. Quinn D, Pagano D, Bosner R, et al. Improved myocardial protection during coronary artery surgery with glucose-insulin-potassium: a randomized controlled trial. J Thoracic Cardiovasc Surgery. 2006;131:34-42.
32. Lazar HL. Hyperglycemia during cardiac surgery (editorial). J Thorac Cardiovasc Surg. 2006;131:11-13.
33. Lazar HL, Chipkin SR, Fitzgerald CA, et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109:1497-1502.
34. van der Horst IC, Timmer JR, Ottervanger JP, et al. Glucose-insulin- potassium and reperfusion in acute myocardial infarction: rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2). Am Heart J. 2005;149:585-591.
35. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437-446.
36. Gentile HT, Seftcheck M, Martin MR. Blood glucose control after acute stroke: a retrospective study. Acad Emerg Med. 2003;10: 432.
37. Hamilton MG, Tranmer BI, Auer RN. Insulin reduction of cerebral infarction due to transient focal ischemia. J Neurosurg. 1997;82:262-268.
38. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32:2426-2432.
39. Pause A, Besham GJ, Gingras AC, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature. 1994;371:762-767.
40. Groeneveld AB, Beishuizen A, Visser FC. Insulin: a wonder drug in the critically ill? Crit Care. 2002;6:102-105.
41. Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia. 2002;45:924-930.
42. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003;31:359-366.
43. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-661.
44. Anger KE, Szumita P. Barriers to glucose control in the intensive care unit. Pharmacotherapy. 2006;26:214-228.
45. McMullin J, Brozek J, Jaeschke R, et al. Glycemic control in the ICU. Intensive Care Med. 2004;30:798-803.
46. Hunt JM. Guest editorial. J Adv Nurs. 1996;23:423-425.
47. Henry P. Overcoming resistance to organizational change. J Am Diet Assoc. 1997;97(suppl l):S145-S147.
48. Buonocore D. Leadership in action: creating a change in practice. AACN Clin Issues. 2004;15:170-181.
49. Brown G, Dodek P. Intravenous insulin nomogram improves blood glucose control in the critically ill. Crit Care Med. 2001;29:1714-1719.
50. Markovitz LJ, Wiechmann RJ, Harris N, et al. Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery. Endocr Pract. 2002;8:10-19.
51. Goldberg PA, Siegel MD, Sherwin RS, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care. 2004;27:461-467.